This trial is active, not recruiting.

Conditions cirrhosis, liver cirrhosis
Treatment colchicine
Phase phase 1
Sponsor National Center for Research Resources (NCRR)
Collaborator Children's Hospital Colorado
Start date May 1990
Trial size 15 participants
Trial identifier NCT00004368, 199/11947, CHD-1089



I. Investigate the efficacy and safety of colchicine therapy in improving hepatic function and reducing hepatic fibrosis (scarring) in children with hepatic cirrhosis.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Primary purpose treatment

Eligibility Criteria

Male or female participants up to 17 years old.

- Advanced hepatic fibrosis or cirrhosis in children - Not pregnant

Additional Information

Description PROTOCOL OUTLINE: Patients receive colchicine orally twice daily for 24 months. After the first month, the dose of colchicine will increase and remain at that dose for the duration of study. Patients are evaluated every 6 months during study.
Trial information was received from ClinicalTrials.gov and was last updated in June 2005.
Information provided to ClinicalTrials.gov by Office of Rare Diseases (ORD).